不同中药疗法治疗腹泻型肠易激综合征:双盲安慰剂对照试验的网络Meta分析
结果显示健脾温肾疗法在改善临床症状和减少不良事件方面排名最佳,疏肝健脾疗法在调节血清素和神经肽Y方面占优;疏肝疗法与健脾疗法仍需进一步研究。
要点
- 健脾温肾疗法在改善IBS-SSS及其腹痛、腹胀、排便不满意、生活质量等维度上排名最佳。
- 健脾温肾疗法不良事件最少,安全性相对最优。
- 疏肝健脾疗法在调节血清素和神经肽Y方面显示优势,可能通过脑-肠轴发挥作用。
核心结论
- 健脾温肾疗法和疏肝健脾疗法是腹泻型肠易激综合征临床症状改善最突出的中药疗法。
- 健脾温肾疗法在减少不良事件方面表现最佳,疏肝健脾疗法在调节血清素和神经肽Y方面占优。
主要发现
- 在成对比较、SUCRA排序和聚类分析中,健脾温肾疗法在改善IBS-SSS、腹痛严重程度、腹痛频率、腹胀严重程度、排便习惯不满意度和生活质量干扰方面均为最佳选择。
- 健脾温肾疗法不良事件少于其他疗法;疏肝健脾疗法在调节血清素和神经肽Y方面显示优势。
关键数值与推荐
- 结局指标包括血清素、神经肽Y、不良事件发生率及IBS-SSS及其子量表(腹痛严重程度、腹痛频率、腹胀严重程度、排便习惯不满意度、生活质量干扰)。
- 采用SUCRA排序和聚类分析比较6种中药疗法,健脾温肾疗法在临床症状综合改善和安全性方面排名最优。
临床怎么用
- 临床可优先考虑健脾温肾疗法以综合改善腹泻型肠易激综合征症状并减少不良事件。
- 疏肝健脾疗法可能通过调节血清素和神经肽Y改善内脏高敏感和动力异常,可作为潜在选择。
局限性
- 样本量较小且可能存在地理发表偏倚,需更多全球范围大样本双盲安慰剂对照试验强化证据。
- 疏肝疗法与健脾疗法的疗效仍需进一步研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ETHNOPHARMACOLOGICAL RELEVANCE: Shuganjianpi Therapy (SGJP), Jianpi Therapy (JP), Shugan Therapy (SG), Jianpiwenshen Therapy (JPWS), and Shuganjianpiwenshen Therapy (SGJPWS), consisting of formulas from Chinese herbal medicine (CHM), have been tremendously applied to irritable bowel syndrome (IBS). However, it remains uncertain when exploring the preferable option among different CHM therapies for diarrhea-predominant irritable bowel syndrome (IBS-D). AIM OF THE STUDY: To compare and rank the efficacy and safety of different CHM therapies for IBS-D. MATERIALS AND METHODS: We searched randomized, double-blinded, placebo-controlled trials through mainstream databases from their inception to October 31, 2022. Eligible randomized controlled trials (RCTs) applied one of the CHM therapies as the experimental group and placebo as the control group. Two authors independently extracted data into a form and evaluated the quality of the retrieved articles by the Cochrane Risk of Bias Tool. At least one of the following outcomes was assessed: Serotonin, Neuropeptide Y (NPY), Incidence of Adverse Events (AE), and Irritable Bowel Syndrome-Severity Scoring System (IBS-SSS) with its subscales of Severity of Abdominal Pain (SAP), Frequency of Abdominal Pain (FAP), Severity of Abdominal Distension (SAD), Dissatisfaction with Bowel Habits (DBH), and Interference with Quality of Life (IQOL). A Bayesian network meta-analysis on a random-effect model was conducted using R 4.2.2 software. RESULTS: 1367 records were retrieved from databases in an initial search. Fourteen studies involving six interventions with 2248 participants were identified. Provided pairwise comparisons, the surface under the cumulative ranking curve (SUCRA) ranking, and cluster analysis, JPWS was the best option for ameliorating clinical symptoms simultaneously, which included IBS-SSS, SAP, FAP, SAD, DBH, and IQOL. As for AE, JPWS contributed to fewer adverse events than others as well. In respect of serum indicators, we noticed the dominance of SGJP in regulating both serotonin and NPY. CONCLUSIONS: JPWS and SGJP were the most prominent CHM therapies for IBS-D in terms of clinical symptoms, including abdominal pain, distension, bowel habits, and improvement of quality of life. The effect of JP and SG for IBS-D required further investigation. As a potential candidate, SGJP may well treat IBS-D by mediating dysmotility, visceral hypersensitivity, and the gut-brain axis with an increase of NPY and a reduction of serotonin. For safety, JPWS was ideal for the fewest adverse events in the treatment of IBS-D. On account of a small sample size and possible geographical publication bias, more double-blinded and placebo-controlled trials with larger samples worldwide would be necessary for strengthening current evidence.
引用
- Liu N, Li J, Wang Y, et al. Different therapies of Chinese herbal medicine for diarrhea-predominant irritable bowel syndrome: A network meta-analysis of double-blinded, placebo-controlled trials. J Ethnopharmacol. 2023. PMID: 37328079. doi:10.1016/j.jep.2023.116672
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。